These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 32630096)

  • 21. T-cell receptor gene-modified cells: past promises, present methodologies and future challenges.
    Tendeiro Rego R; Morris EC; Lowdell MW
    Cytotherapy; 2019 Mar; 21(3):341-357. PubMed ID: 30655164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.
    Ramos CA; Dotti G
    Expert Opin Biol Ther; 2011 Jul; 11(7):855-73. PubMed ID: 21463133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
    Hughes-Parry HE; Cross RS; Jenkins MR
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers.
    Tay JC; Zha S; Wang S
    Immunotherapy; 2017 Dec; 9(16):1339-1349. PubMed ID: 29185393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designer T-cells and T-cell receptors for customized cancer immunotherapies.
    Legut M; Sewell AK
    Curr Opin Pharmacol; 2018 Aug; 41():96-103. PubMed ID: 29852403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric antigen receptor-modified T cells strike back.
    Frigault MJ; Maus MV
    Int Immunol; 2016 Jul; 28(7):355-63. PubMed ID: 27021308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adoptive CD8
    Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
    Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene-modified hematopoietic stem cells for cancer immunotherapy.
    Larson S; De Oliveira SN
    Hum Vaccin Immunother; 2014; 10(4):982-5. PubMed ID: 24398603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic stem cells for cancer immunotherapy.
    Gschweng E; De Oliveira S; Kohn DB
    Immunol Rev; 2014 Jan; 257(1):237-49. PubMed ID: 24329801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
    Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
    Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
    Shum T; Kruse RL; Rooney CM
    Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
    Atanackovic D; Radhakrishnan SV; Bhardwaj N; Luetkens T
    Br J Haematol; 2016 Mar; 172(5):685-98. PubMed ID: 26791002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.
    Torikai H; Cooper LJ
    Mol Ther; 2016 Aug; 24(7):1178-86. PubMed ID: 27203439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term surviving cancer patients as a source of therapeutic TCR.
    Inderberg EM; Wälchli S
    Cancer Immunol Immunother; 2020 May; 69(5):859-865. PubMed ID: 31915853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
    Perez C; Gruber I; Arber C
    Front Immunol; 2020; 11():583716. PubMed ID: 33262761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Redirected T cells in cancer therapy.
    Sangiolo D
    Expert Opin Biol Ther; 2015; 15(12):1667-70. PubMed ID: 26515608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
    Chen N; Li X; Chintala NK; Tano ZE; Adusumilli PS
    Curr Opin Immunol; 2018 Apr; 51():103-110. PubMed ID: 29554494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
    Stauss HJ; Morris EC
    Gene Ther; 2013 Nov; 20(11):1029-32. PubMed ID: 23804078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From CARs to TRUCKs and Beyond: Safely en Route to Adoptive T-cell Therapy for Cancer.
    Dummy
    EBioMedicine; 2016 Dec; 14():1-2. PubMed ID: 27986279
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.